合成抗凝药八糖parin通过DC-SIGN/NF-κB信号减轻肾缺血再灌注损伤
本研究在小鼠肾缺血再灌注损伤模型及缺氧/复氧肾小管上皮细胞中评估合成硫酸八糖octaparin的疗效。Octaparin改善肾功能、减轻小管坏死与纤维化、抑制氧化应激和炎症,并减少组织因子表达与纤维蛋白沉积。机制上octaparin结合DC-SIGN抑制NF-κB磷酸化与核转位,发挥不同于经典肝素抗凝的多重肾保护作用。
要点
- Octaparin改善小鼠肾IRI肾功能并减轻小管坏死与纤维化。
- Octaparin抑制氧化应激、炎症、凋亡及凝血炎症反应。
- 其肾保护机制为结合DC-SIGN抑制NF-κB激活,非经典抗凝途径。
核心结论
- Octaparin通过调控DC-SIGN/NF-κB信号在肾IRI中发挥多重肾保护作用。
- Octaparin可同时抑制血栓炎症、氧化应激和凋亡,且不伴常规肝素相关风险。
研究设计与样本
- 研究采用小鼠肾缺血再灌注损伤模型及缺氧/复氧损伤的肾小管上皮细胞。
- 系统评估肾功能、组织病理、纤维化、凋亡、氧化应激、炎症及凝血指标。
- 通过分子对接、受体阻断实验和免疫印迹分析DC-SIGN结合与NF-κB信号。
主要发现
- Octaparin显著改善小鼠肾功能,减轻小管坏死和纤维化并抑制凋亡。
- Octaparin降低氧化应激、恢复抗氧化酶活性、下调促炎因子并减少中性粒细胞浸润。
- Octaparin抑制组织因子表达和纤维蛋白沉积,缓解血栓炎症反应。
- 体外实验中octaparin抑制活性氧爆发、恢复抗氧化防御、减少炎症因子释放并抑制凋亡。
- 机制上octaparin结合肾上皮细胞DC-SIGN,抑制NF-κB磷酸化及核转位。
临床怎么用
- Octaparin可能作为肾IRI相关急性肾损伤的候选治疗策略,但尚需临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Renal ischemia-reperfusion injury (IRI) contributes to acute kidney injury by inducing oxidative stress, inflammation, and thromboinflammatory responses. Conventional heparins mitigate IRI, but their use is limited by bleeding and thrombocytopenia. OBJECTIVES: To evaluate octaparin, a structurally defined synthetic sulfated octasaccharide with anticoagulant activity and minimal bleeding risk, as a novel therapeutic for IRI. METHODS: Murine renal IRI models and hypoxia/reoxygenation-injured renal tubular epithelial cells were treated with octaparin. Renal function, histopathological changes, fibrosis, apoptosis, oxidative stress, inflammation, and coagulation parameters were systematically evaluated. Dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) engagement and nuclear factor (NF)-κB signaling were analyzed by molecular docking, receptor blockade experiments, and immunoblotting. RESULTS: Octaparin significantly improved renal function in vivo, attenuated tubular necrosis and fibrosis, and suppressed apoptosis. It also markedly reduced oxidative stress, restored antioxidant enzyme activity, downregulated proinflammatory cytokines, and reduced neutrophil infiltration. In terms of coagulation, octaparin inhibited tissue factor expression and fibrin deposition, thereby alleviating thromboinflammatory responses. In vitro, octaparin similarly suppressed excessive reactive oxygen species bursts, restored antioxidant defenses, reduced inflammatory cytokine release, and inhibited apoptosis in hypoxia/reoxygenation-injured renal tubular epithelial cells. Mechanistically, octaparin binds to the DC-SIGN receptor on renal epithelial cells, inhibiting NF-κB phosphorylation and nuclear translocation, thereby disrupting reactive oxygen species-driven inflammatory cascades via a pathway distinct from classical heparin anticoagulation. CONCLUSION: Octaparin exerts multifaceted renoprotective effects in IRI by modulating DC-SIGN/NF-κB signaling. Its ability to simultaneously suppress thromboinflammation, oxidative stress, and apoptosis-without the risks associated with conventional heparins-represents a transformative therapeutic strategy for acute kidney injury.
引用
- Yu N, Fang R, Zhang Y, et al. A synthetic anticoagulant, octaparin, attenuates renal ischemia-reperfusion injury via dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin/nuclear factor κB signaling. J Thromb Haemost. 2026. PMID: 41581761. doi:10.1016/j.jtha.2025.12.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。